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Background: This study aims to introduce the diagnosis and surgical treatment of the rare disease multiple
endocrine neoplasia type 2A (MEN 2A).
Methods: Thirteen cases of MEN 2A were diagnosed as medullary thyroid carcinoma (MTC) and
pheochromocytoma by biochemical tests and imaging examination. They were treated by bilateral adrenal tumor
excision or laparoscopic surgery.
Results: Nine patients were treated by bilateral adrenal tumor excision and the remaining four were treated by
laparoscopic surgery for pheochromocytoma. Ten patients were treated by total thyroidectomy and bilateral lymph
nodes dissection and the remaining three were treated by unilateral thyroidectomy for MTC. Up to now, three
patients have died of MTC distant metastasis.
Conclusions: We confirmed that MEN 2A can be diagnosed by biochemical tests and imaging examination when
genetic testing is not available. Surgical excision is the predominant way to treat MEN 2A; pheochromocytoma
should be excised at first when pheochromocytoma and MTC occur simultaneously.
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Multiple endocrine neoplasia type 2 (MEN 2) is an
inherited syndrome which affects many endocrine
glands. Generally, MEN 2 is divided into three subtypes:
MEN 2A, MEN 2B, and familial medullary thyroid car-
cinoma [1]. MEN 2A, also known as Sipple syndrome, is
a very rare disease. More than 80% of MEN 2 cases are
MEN 2A and its prevalence is approximately 1 in 25,000
[2,3]. Genetic testing is currently the main method of
MEN 2A diagnosis in developed countries. However, it
has not yet been extensively spread in developing coun-
tries because of economic and technical limitations.
Therefore, MEN 2A is normally diagnosed by biochem-
ical tests and imaging examinations [4,5]. Surgical exci-
sion is the predominant treatment of MEN 2A. The
present study aims to describe this disease and to im-
prove people’s awareness about the diagnosis and treat-
ment of MEN 2A.* Correspondence: chhyangch@126.com
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Ethical statement
Any experimental research that is reported in the manu-
script have been performed with the approval of Re-
search Ethics Committee of General Hospital of Tianjin
Medical University. Research carried out on humans was
in compliance with the Helsinki Declaration.Patients
Thirteen MEN 2A patients (2 male and 11 female; mean
age, 37.9 years; mean course of disease, 1.8 years) were
admitted to our hospital from 1988 to 2011. Ten of 13
patients were diagnosed as MEN 2A after presenting
with paroxysmal hypertension, cardiopalmus, and dizzi-
ness, and the remaining 3 were diagnosed following a
physical examination. MTC occurred earlier than pheo-
chromocytoma in 8 cases; MTC and pheochromocytoma
occurred simultaneously in 5 cases. No patients showed
hyperparathyroidism.d. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 2 Enhanced CT scanning of the adrenal gland shows a
round-like cystic solid mass located at the right adrenal gland
(Black arrow). Inside of the mass, multiple punctate and dense
shadows are visible. The boundary of the mass is manifested as
inhomogeneous enhancement. Mass center shows a lamellar
non-enhanced area and separation.
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Twenty-hour urinary vanillylmandelic acid (VMA) was
tested in all patients. Its levels were significantly elevated
in 10 patients and the highest was 950 μmol/L (normal
24–70 μmol/L). Serum calcitonin levels were highly in-
creased in 7 cases and the highest was 3,470 μmol/L
(normal 28–133 μmol/L). Parathyroid hormone levels
were normal in 10 patients.
Adrenal B-mode ultrasonography was performed in 13
patients. We found 9 cases of bilateral lesions, 1 case of
left side lesion, 2 cases of right side lesions, and 1 case
of ectopic pheochromocytoma located at one side of the
abdominal aorta. Computed tomography (CT) of adrenal
gland was performed in 10 patients. The images revealed
uneven mass with intact capsules (Figure 1) and they
were more obvious on enhanced CT images (Figure 2).
Magnetic resonance imaging (MRI) was performed in 4
patients and the images showed even or uneven masses
with intact capsules. Thyroid B-mode ultrasonography
was performed in 13 patients and revealed low echo-
genic regions with uneven echo. Thyroid CT was per-
formed in 10 patients and showed inhomogeneous low
density images (Figure 3).
Surgical and medical treatment
All patients were treated with surgical operation; 9 pa-
tients received adrenal open operation and the remaining
4 received peritoneoscope minimally invasive treatment.
All excised masses had intact capsules and were proven
to be pheochromocytoma (Figure 4). Radical thyroidec-
tomy and neck lymph node dissection were performed in
10 patients. Three patients were treated by unilateralFigure 1 Plain CT scanning of the adrenal gland shows a
uneven mass (Black arrow, about 6.2 × 6.7 × 7.8 cm) with intact
capsule and punctate calcifications located at the right adrenal
gland, which shares a unclear boundary with margo
interior hepatics.
Figure 3 Enhanced CT scanning of the thyroid gland shows a
cystic-solid low density mass, which is located underneath
lateral lobes of the thyroid gland and manifested as
inhomogeneous enhancement (Black arrow). Inside of the mass,
a lamellar non-enhanced area is visible. The mass is projected into
the gaps of surrounding vessels. The cervical part shows no obvious
enlarged lymph nodes.
Figure 4 Pathologically diagnosed adrenal pheochromocytoma
(HE × 400) shows a wide variety of tissue structure and cell
morphology. Tumor tissue is separated into lobulated parts by
fibrous bands come from envelope. Tumor cells (most are
polygonal, few are fusiform and prismatical) are mostly arranged in
cords, nests, and pieces, which are separated by thin-walled blood
sinuses and fibrous tissues rich in blood vessels. Tumor cells show
unclear boundaries and have lots of cytoplasm as well as
inhomogeneous particles (slightly basophilic or amphophilic).
Tumor cell nucleus is round or oval, which has obvious nucleolus
and little karyokinesis.
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5, 7, and 10 years after initial thyroidectomy because of
their MTC recurrence. Pheochromocytoma was excised in
advance and thyroidectomy was performed 2 weeks later
in the 5 cases with MTC and pheochromocytoma oc-
curred simultaneously. All patients were treated with oral
thyroxin tablet after surgery and 6 patients took prednis-
one together. Both medicines were taken perpetually.
Patients were followed-up after surgery for tumor recur-
rence. The following items were included in the follow-up:
family illness history, biochemical tests (serum calcitonin,
cortisol, thyroid hormone, urinary VMA), and imaging
examination (ultrasound, CT).
Results
Patients’ primary symptoms related to pheochromocy-
toma disappeared after operation. Ten cases had normal
blood pressure and the remaining 3 had hypertension.
VMA of one patient was higher than normal after sur-
gery and one adrenal lump was discovered at the oppos-
ite side of surgical position in this patient 3 years later.
It was subsequently excised and proven to be pheochro-
mocytoma. Ten patients are still alive and 3 patients
died of MTC distant metastasis at the time of writing
this manuscript.
Discussion
MEN 2A is an autosomal dominant syndrome involving
multiple endocrine glands. It is characterized by MTC,pheochromocytoma, and hyperparathyroidism. MTC oc-
curs in nearly all MEN 2A patients and is generally the
first manifestation of MEN2A, whereas pheochromocy-
toma and hyperparathyroidism occurs in 30%–50% and
20% of MEN 2A patients, respectively [6,7]. Hyperpara-
thyroidism is mainly due to diffuse hyperplasia of the
parathyroid glands and not to adenoma. The syndrome
affects all ages and both sexes with equal frequency.
However, all of our 13 patients presented with MTC and
pheochromocytoma without hyperparathyroidism, there
were more female patients (n = 11) than male patients
(n = 2). These deviations may be related to the small
sample size.
MEN 2A is associated with germ line mutation of RET
proto-oncogene [8]. Genetic testing can detect missense
mutation of RET proto-oncogene, which makes it a reli-
able method to diagnosis MEN 2A [9]. However, we
could not perform this test because of technical limita-
tions. MTC tumor cells can produce many biochemical
substances, such as calcitonin, adrenocorticotropic hor-
mone, histamine, and carcinoembryonic antigen. Calci-
tonin is a specific tumor marker which is critical in the
diagnosis of MTC as well as in determining whether the
tumor has been completely excised and in monitoring of
tumor recurrence [10-12]. Generally, serum calcitonin
levels of MTC patients are higher than normal [13].
Pheochromocytoma is an adrenal gland tumor that pro-
duces excess adrenaline; VMA is a terminal metabolite
of adrenaline. Some researchers have demonstrated that
urinary VMA is specific and sensitive to the diagnosis of
pheochromocytoma [14,15]. The detection of serum cal-
cium and parathyroid hormone can improve the detec-
tion rate of MEN 2A [16].
Imaging examinations such as B-mode ultrasonog-
raphy, MRI, and CT, play a vital role in initial tumor
localization and the management of MEN 2A [17].
Specifically, B-mode ultrasonography is the preferred
method of diagnosis and localizing MTC and coexisting
parathyroid hyperplasia or adenoma. CT examination is
the first choice for localizing pheochromocytoma. Al-
though MRI has inferior localizing capability when com-
pared with CT and B-mode ultrasonography, it is very
helpful to explore tumor invasion as well as the relation-
ship between the tumor and the great vessels.
Surgical excision is the main mode of management of
MEN 2A patients. Pheochromocytoma should be excised
initially in those patients with simultaneous MTC and
pheochromocytoma. Otherwise, surgeries may lead to the
onset of fatal hypertension [18]. Moreover, preoperative
preparation should be done thoroughly by using 2 weeks
of specific α-receptor blocker and 1 week of intravenous
infusion. In MEN 2A patients, most pheochromocytomas
are bilateral in nature, and should be preferably removed
by bilateral tumor excision. Abdominal incision or curved
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ation [19]. In our study, 9 of 13 patients were diagnosed
with bilateral pheochromocytoma and all of them under-
went bilateral tumor excision. However, it should be noted
that, in order to prevent adrenal crisis, prednisone hor-
mone replacement therapy should be performed during
and after surgery. Laparoscopy, a newly developed minim-
ally invasive approach, which can lead to minor intraoper-
ative injury and rapid postoperative recovery, was
performed in 4 cases of unilateral pheochromocytoma
MEN 2A patients and their pheochromocytoma was suc-
cessfully removed.
MEN 2A-related MTC is susceptible to cervical lymph
node metastasis and hematogeneous spread; therefore,
total thyroidectomy with bilateral lymph node dissection
should be carried out and the parathyroid glands should
be explored at the same time even in unilateral MTC
[20]. As for our patients, 10 patients received total thy-
roidectomy and bilateral lymph node dissection, the
remaining 3 were treated by unilateral thyroidectomy
and their remained thyroid was separately excised 5, 7,
and 10 years after first operation because of MTC recur-
rence. Because the thyroid surgery of these 3 patients
was performed in a junior hospital, the neck dissection
was not performed at the same time due to the limited
medical level.
Prognosis of MEN 2A is primarily dependent upon
the staging of MTC [21]. Therefore, it is very important
to monitor serum calcitonin regularly. It is recom-
mended that serum calcitonin should be examined 1, 3,
6, and 12 months after initial thyroidectomy and twice
a year thereafter. B-mode ultrasonography or CT exam-
ination of the neck should be performed once a year to
find the recurrence and metastasis of MTC and the
prognosis of MEN 2A timely. Three patients were diag-
nosed with MTC recurrence by serum calcitonin test
during follow-up.
Conclusions
In conclusion, MEN 2A can be diagnosed by biochem-
ical tests and imaging examination when genetic testing
is not available. Surgical excision is the predominant way
to treat MEN 2A and pheochromocytoma should be ex-
cised at first when pheochromocytoma and MTC occur
simultaneously.
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